Congressional Hearing: Examining the Drug Supply Chain
January 1, 2018
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
The hearing provides a public record of the arguments and perspectives from major healthcare industry stakeholders regarding how drugs move from manufacturers to patients, which informs future federal legislation on drug costs and supply chain regulation.
Potentially affected actors named in the source documents. Mention is not a position.
Pharmaceutical Manufacturers
Industry representatives provided testimony on their role in drug development and pricing.
Pharmacy Benefit Managers
Industry representatives provided testimony on their role in negotiating drug prices and managing pharmacy networks.
Patients
The outcomes of supply chain regulations discussed in the hearing may influence the cost and accessibility of prescription drugs.
Last recorded activity January 1, 2018.
Next step not available in the current record.
Summary
Key Facts
- The hearing was held on December 13, 2017, by the House Subcommittee on Health.
- The session focused on the roles of various entities in the drug supply chain, including manufacturers, distributors, and pharmacy benefit managers.
- Witnesses included representatives from PhRMA, the Biotechnology Innovation Organization, the Association for Accessible Medicines, the Healthcare Distribution Alliance, the Pharmaceutical Care Management Association, America's Health Insurance Plans, and the American Hospital Association.
- The transcript includes prepared statements and answers to follow-up questions from all seven testifying organizations.
- The hearing is officially recorded as Serial No. 115-88 of the 115th Congress.
Frequently Asked Questions
What is the purpose of this hearing?
Who testified at this hearing?
Why It Matters
The hearing provides a public record of the arguments and perspectives from major healthcare industry stakeholders regarding how drugs move from manufacturers to patients, which informs future federal legislation on drug costs and supply chain regulation.
News Coverage
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Broad Stakeholder Engagement
The hearing brought together a wide spectrum of the supply chain, from manufacturers to insurers and hospitals, indicating a comprehensive approach to investigating drug pricing.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz15Current news / social attention level
Publisher tools